Mumps Virus

For adults who do not have evidence of immunity, the standard dosage is typically one or two doses of the Mumps Virus-containing vaccine (MMR).

• Standard Adult Dose: 0.5 mL administered subcutaneously.
• High-Risk Adults: Healthcare workers, international travelers, and students in post-secondary educational institutions should receive two doses, separated by at least 28 days, unless they have other evidence of immunity (such as laboratory confirmation of disease or positive IgG titers).

The pediatric vaccination schedule is strictly regulated to ensure maximum seroconversion (the development of antibodies).

• First Dose: 0.5 mL at 12 through 15 months of age.
• Second Dose: 0.5 mL at 4 through 6 years of age (prior to elementary school entry).
• Minimum Interval: The second dose may be administered earlier than age 4, provided at least 28 days have elapsed since the first dose.

Renal Impairment

No dosage adjustments are required for patients with renal impairment, as the vaccine is not cleared by the kidneys.

Hepatic Impairment

No dosage adjustments are required for patients with hepatic impairment.

Elderly Patients

Most adults born before 1957 are considered immune due to natural exposure. However, if vaccination is required, the standard 0.5 mL dose is used. Clinical trials have not identified specific safety concerns unique to the geriatric population, though the immune response may be slightly less robust due to immunosenescence (age-related decline in immune function).

• Route: Mumps Virus must be administered via subcutaneous injection. It should never be given intravenously.
• Site: In children, the preferred site is the outer aspect of the upper arm or the anterolateral thigh. In adults, the outer aspect of the upper arm (deltoid region) is typically used.
• Preparation: The vaccine comes as a freeze-dried (lyophilized) powder. It must be reconstituted only with the diluent provided by the manufacturer. Once reconstituted, the vaccine should be administered immediately (within 8 hours if refrigerated) to ensure viral viability.
• Storage: The lyophilized vaccine must be stored in a refrigerator (2°C to 8°C / 36°F to 46°F) or freezer (-50°C to -15°C / -58°F to +5°F). The diluent can be stored at room temperature or in the refrigerator.

If a child or adult misses a scheduled dose, it should be administered as soon as possible. There is no need to restart the series; simply continue with the remaining doses according to the recommended intervals. This is often referred to as 'catch-up vaccination.'

Overdose with Mumps Virus vaccine is extremely rare and typically involves the administration of a second dose too close to the first. While not life-threatening, it may increase the risk of local injection site reactions (swelling, redness). In the event of an accidental overdose, the patient should be monitored for acute allergic reactions.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip scheduled immunizations without medical guidance.

Most side effects from the Mumps Virus vaccine are mild and indicate that the body is building protection. These typically appear within 24 to 48 hours, though some (like fever or rash) may be delayed by 5 to 12 days as the attenuated virus replicates.

• Injection Site Reactions: Redness, swelling, and tenderness at the site of the shot. This usually resolves within 2-3 days.
• Fever: A low-grade fever (under 101°F) is common.
• Malaise: A general feeling of discomfort or tiredness (fatigue).

• Rash: A mild, non-contagious rash that may look like mumps or measles. This typically occurs 7-10 days after vaccination.
• Parotitis: Mild swelling of the salivary glands (parotid glands), mimicking a very mild case of mumps. This occurs in less than 1% of vaccinees.
• Joint Pain (Arthralgia): More common in adult women than in children, this usually affects the small joints of the hands and feet and is transient.

• Febrile Seizures: These are convulsions triggered by fever. While frightening, they are generally harmless and do not cause long-term brain damage. The risk is slightly higher with the MMRV combination vaccine than with MMR and Varicella given separately.
• Thrombocytopenia: A temporary decrease in blood platelets (cells that help blood clot), which may lead to easy bruising or bleeding.
• Orchitis: Inflammation of the testicles. This is extremely rare following vaccination compared to natural mumps infection.

> Warning: Stop taking Mumps Virus and call your doctor immediately if you experience any of these symptoms after vaccination.

• Anaphylaxis: A severe allergic reaction characterized by hives, swelling of the face or throat, difficulty breathing, and a rapid heartbeat. This usually occurs within minutes of the injection.
• Neurological Changes: Extreme drowsiness, confusion, or changes in behavior.
• High Fever: A temperature exceeding 103°F (39.4°C) that does not respond to acetaminophen or ibuprofen.
• Severe Pain: Intense pain in the joints or limbs that prevents normal movement.

There is no credible scientific evidence linking the Mumps Virus vaccine to long-term chronic conditions such as autism, Type 1 diabetes, or inflammatory bowel disease. Extensive studies by the Institute of Medicine (IOM) and the CDC have consistently shown that the vaccine is safe for the general population. The most significant 'long-term' effect is the persistence of protective antibodies, which may last a lifetime in most individuals.

No FDA black box warnings for Mumps Virus. However, there are strict contraindications regarding pregnancy and severe immunodeficiency that must be observed.

Report any unusual symptoms or suspected adverse events to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or online at vaers.hhs.gov.

Before receiving the Mumps Virus vaccine, patients must be screened for underlying health conditions that could affect their response to a live vaccine. Because this vaccine contains a live, albeit weakened, virus, it can cause severe disease in individuals whose immune systems cannot control viral replication.

No FDA black box warnings for Mumps Virus. Unlike some high-risk medications, vaccines are generally held to a different regulatory standard focusing on preventative safety profiles.

• Allergic Reactions: The Mumps Virus vaccine is produced in chick embryo cell cultures and contains trace amounts of neomycin and gelatin. Individuals with a history of anaphylactic reactions to neomycin or gelatin should not receive the vaccine. Most individuals with egg allergies can safely receive the vaccine, as it does not contain significant egg protein.
• Immunosuppression: Patients with primary or acquired immunodeficiency (e.g., HIV/AIDS, leukemia, lymphoma, or those receiving systemic high-dose corticosteroids or chemotherapy) are at risk of disseminated viral infection. Vaccination should be deferred until immune function is restored.
• Acute Illness: Vaccination should be postponed in individuals with moderate to severe acute illness, with or without fever, to avoid diagnostic confusion between the illness and vaccine side effects.
• Family History of Seizures: Healthcare providers should exercise caution and closely monitor children with a personal or strong family history of seizures when administering the MMRV combination.

There are no routine lab tests required after vaccination for most people. However, in certain clinical settings, the following may be monitored:

• IgG Titers: To confirm seroconversion in high-risk individuals (e.g., healthcare workers).
• Platelet Counts: If symptoms of easy bruising or petechiae (small red spots on the skin) appear.

The Mumps Virus vaccine has no known effect on the ability to drive or operate heavy machinery. However, if a patient experiences post-vaccination dizziness or syncope (fainting), they should wait until symptoms resolve.

There is no direct interaction between alcohol and the Mumps Virus vaccine. However, heavy alcohol consumption can suppress the immune system, potentially leading to a less effective response to the vaccine.

As this is a vaccine administered in discrete doses rather than a daily medication, 'discontinuation' refers to stopping the vaccination series. Failing to complete the two-dose series leaves the individual at higher risk for mumps, particularly during outbreaks where one dose may only be 78% effective compared to 88% for two doses.

> Important: Discuss all your medical conditions, especially any history of immune system problems, with your healthcare provider before starting Mumps Virus.

• Severe Immunosuppressants: Drugs like mycophenolate, tacrolimus, or high-dose methotrexate should not be used concurrently with a live virus vaccine. The clinical consequence is the risk of vaccine-derived viral infection.
• Recent Blood Products: Immune Globulin (IG), whole blood, or plasma can interfere with the 'take' (efficacy) of the vaccine. The antibodies in these products may neutralize the attenuated virus before it can stimulate the patient's own immune system.

• Systemic Corticosteroids: Patients taking 20 mg or more of prednisone (or equivalent) daily for more than two weeks should wait at least one month after stopping the steroid before receiving the Mumps Virus vaccine.
• Chemotherapy/Radiation: Vaccination should be delayed until at least three months after the completion of immunosuppressive therapy.

• Other Live Vaccines: If Mumps Virus (as MMR) is not given on the same day as other live vaccines (like Varicella or Yellow Fever), the doses should be separated by at least 4 weeks. This prevents the first vaccine's interferon response from interfering with the replication of the second vaccine.
• Tuberculin Skin Test (PPD): The Mumps Virus vaccine can temporarily suppress the T-cell response, leading to a false-negative PPD result. The skin test should be done on the same day as vaccination or delayed by 4-6 weeks.

There are no known food interactions with the Mumps Virus vaccine. It can be administered regardless of the timing of meals.

While no specific herbal interactions are documented, any supplement that significantly alters immune function (e.g., high-dose echinacea or pharmacological doses of certain antioxidants) should be discussed with a provider, although they are unlikely to contraindicate vaccination.

• Interferon-Gamma Release Assays (IGRAs): Similar to the PPD test, live vaccines may cause temporary false-negative results in TB blood tests.
• Viral Cultures: If a patient is swabbed for mumps shortly after vaccination, the vaccine strain may be detected, which must be distinguished from the wild-type virus via specialized laboratory testing.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect the immune system.

• Pregnancy: The Mumps Virus vaccine must NEVER be given to pregnant women. There is a theoretical risk that the live attenuated virus could cross the placenta and infect the fetus. Women should be advised to avoid pregnancy for at least 28 days after receiving the vaccine.
• Severe Allergic Reaction: Anyone who has had a life-threatening allergic reaction to a previous dose of a mumps-containing vaccine or to any component of the vaccine (including neomycin or gelatin) must not receive it.
• Severe Immunodeficiency: This includes patients with cellular immune deficiency, hypogammaglobulinemia, or advanced HIV infection with severe immunosuppression (CD4 counts <15% or <200 cells/mm³ in adults).

• Recent Receipt of Antibody-Containing Products: If a patient has received a blood transfusion or immune globulin, vaccination should be delayed for 3 to 11 months, depending on the product and dose, to ensure the vaccine is effective.
• Family History of Immunodeficiency: Vaccination should be deferred in children with a family history of congenital or hereditary immunodeficiency until the child's immune status is evaluated and confirmed to be normal.
• Thrombocytopenia History: Individuals who developed thrombocytopenia after the first dose of MMR should be carefully evaluated before receiving a second dose, as the risk of recurrence is present.

Patients with known hypersensitivity to neomycin (often used in topical ointments) may experience a delayed-type contact dermatitis. While this is not an absolute contraindication to the systemic injection, a history of anaphylaxis to neomycin is an absolute contraindication.

> Important: Your healthcare provider will evaluate your complete medical history and current immune status before prescribing or administering the Mumps Virus vaccine.

Mumps Virus is classified as Pregnancy Category C (though strictly contraindicated). While no cases of 'Congenital Mumps Syndrome' have been documented from the vaccine, the theoretical risk of fetal infection remains. If a pregnant woman is inadvertently vaccinated, she should be counseled on the theoretical risk, but this is generally not considered an indication for termination of pregnancy. Women of childbearing age should be screened for pregnancy and advised to use effective contraception for 4 weeks post-vaccination.

Studies have shown that the Mumps Virus vaccine does not pose a risk to breastfeeding infants. While some vaccine-derived viruses (like Rubella) may be secreted in breast milk, they do not cause illness in the nursing child. Breastfeeding is not a contraindication to vaccination for the mother.

The Mumps Virus vaccine is approved for use in children as young as 12 months. In some cases, such as international travel to endemic areas, it may be given to infants aged 6-11 months; however, this dose does not count toward the two-dose series because the infant's maternal antibodies may interfere with the immune response.

Most adults born before 1957 are presumed to have natural immunity. For those who do not, the vaccine is safe. Clinical data suggest that the elderly may have a slightly lower antibody response, but the vaccine remains the best method for preventing mumps-related complications (such as meningitis) in this age group.

Patients with chronic kidney disease or those on dialysis can safely receive the Mumps Virus vaccine, provided they are not otherwise immunosuppressed. No dose adjustment is needed.

Patients with liver disease can receive the vaccine. In patients with end-stage liver disease awaiting transplant, vaccination should be completed well in advance of the transplant to ensure the patient is protected before they begin lifelong immunosuppressive therapy.

> Important: Special populations, particularly those with altered immune states or those planning pregnancy, require individualized medical assessment by an immunology or infectious disease specialist.

The Mumps Virus (Live Attenuated) vaccine acts as an immunizing agent. It contains the Jeryl Lynn strain of the mumps virus, which has been 'passaged' through chick embryo cells numerous times. This process causes the virus to lose its virulence (ability to cause disease) while retaining its immunogenicity (ability to trigger an immune response). Upon injection, the virus infects host cells and replicates, leading to the production of viral proteins that are recognized by the immune system. This induces the production of neutralizing antibodies and activates cytotoxic T-cells.

The pharmacodynamic effect is the 'seroconversion' rate. Following a single dose of the mumps vaccine, approximately 78% to 91% of individuals develop protective antibodies. After two doses, the seroconversion rate increases to approximately 88% to 95%. The onset of protection typically occurs 2 to 4 weeks after administration. The duration of effect is long-term, often providing protection for several decades, though 'waning immunity' can occur in some individuals.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous Injection) |

| Protein Binding | N/A |

| Onset of Immunity | 14-28 days |

| Duration of Immunity | 20+ years in most individuals |

| Metabolism | Cellular degradation by immune cells |

| Excretion | Not renally or fecally excreted |

The vaccine consists of the live attenuated mumps virus. It is a single-stranded, negative-sense RNA virus. The vaccine is provided as a sterile, lyophilized cake or powder. It contains stabilizers such as sorbitol and hydrolyzed gelatin, and trace amounts of neomycin. It does not contain thimerosal or other preservatives.

Mumps Virus is categorized as a Live Attenuated Viral Vaccine. It is often grouped with other childhood immunizations under the broader class of Active Immunizing Agents. Within the EPC (Established Pharmacologic Class) system, it is recognized as a vaccine component for the prevention of viral infection.